Perioperative nivolumab plus neoadjuvant chemotherapy did not significantly improve pCR rate or event-free survival in MIBC.
|Videos|November 6, 2017
Dr. Mikhail on Ongoing Clinical Trials for Patients With Myeloma
Author(s)Sameh Mikhail, MD
Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discusses ongoing clinical trials for patients with myeloma.
Advertisement
Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discusses ongoing clinical trials for patients with myeloma.
Current studies are looking at stem cell transplants in patients with myeloma. There are a lot of immunomodulatory agents and combinations being looked at, says Mikhail.
Immunotherapy for patients with multiple myeloma is also being scrutinized for its safety concerns, but it appears to show encouraging results in other settings, explains Mikhail.
Advertisement
Related to this article
MajesTEC-9 data supported an EU indication expansion for teclistamab in relapsed/refractory multiple myeloma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The NCCN update adds locally advanced CSCC to the category 2A listing that cosibelimab received for metastatic disease in 2025.
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.
Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
Advertisement
Advertisement
Trending on OncLive
1
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
2
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
3
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
4
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
5